Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuan Long

Showing results (221-230 of 224) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 224 results.
Journal of Asian Natural Products Research|March 12, 2025
Lifei Qingchang Tang attenuates acute lung injury <i>via</i> the NF-κB and MAPK signaling pathwaysQi-Fen Huang, Jia-Min Zeng, Yuan-Long Hu, et al.
Frontiers in Pharmacology|June 12, 2024
Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trialChun-Li Lu, Liu-Qing Yang, Xin-Yan Jin, et al.
American Journal of Epidemiology|December 21, 2012
Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern ChinaZhiwei Liu, Ming-Fang Ji, Qi-Hong Huang, et al.
Signal Transduction and Targeted Therapy|April 13, 2025
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trialHuijie Bian, Liang Chen, Zheng Zhang, et al.
Pageof 23

Showing results (221-230 of 224) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 224 results.
Journal of Asian Natural Products Research|March 12, 2025
Lifei Qingchang Tang attenuates acute lung injury <i>via</i> the NF-κB and MAPK signaling pathwaysQi-Fen Huang, Jia-Min Zeng, Yuan-Long Hu, et al.
Frontiers in Pharmacology|June 12, 2024
Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trialChun-Li Lu, Liu-Qing Yang, Xin-Yan Jin, et al.
American Journal of Epidemiology|December 21, 2012
Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern ChinaZhiwei Liu, Ming-Fang Ji, Qi-Hong Huang, et al.
Signal Transduction and Targeted Therapy|April 13, 2025
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trialHuijie Bian, Liang Chen, Zheng Zhang, et al.
Pageof 23